每經記者｜許立波(bo)    每經編輯｜魏官紅    

8月4日(ri)盤后，康恩貝（SH600572，股(gu)價5.43元，市值139.55億(yi)元）發布2023年半年度業(ye)績快(kuai)報(bao)，報(bao)告(gao)期內，公司實現營業(ye)總收(shou)入37.65億(yi)元，同(tong)比(bi)增長22.19%；實現歸母凈利潤5.16億(yi)元，同(tong)比(bi)增長143.01%。

康(kang)恩貝(bei)稱(cheng)，公司各業(ye)(ye)務(wu)(wu)(wu)板塊營(ying)(ying)(ying)收(shou)(shou)較上(shang)年(nian)同(tong)(tong)(tong)期均有不同(tong)(tong)(tong)幅度(du)的增長(chang)(chang)(chang)(chang)，業(ye)(ye)務(wu)(wu)(wu)結構進一步優化。具體來看(kan)，今年(nian)上(shang)半(ban)年(nian)，中(zhong)藥大健(jian)康(kang)業(ye)(ye)務(wu)(wu)(wu)實現(xian)(xian)營(ying)(ying)(ying)收(shou)(shou)25.18億(yi)元(yuan)(yuan)，較上(shang)年(nian)同(tong)(tong)(tong)期增長(chang)(chang)(chang)(chang)32.22%，占公司總營(ying)(ying)(ying)收(shou)(shou)比(bi)重66.88%，占比(bi)進一步提升。自我保健(jian)產品業(ye)(ye)務(wu)(wu)(wu)實現(xian)(xian)營(ying)(ying)(ying)收(shou)(shou)17.77億(yi)元(yuan)(yuan)，同(tong)(tong)(tong)比(bi)增長(chang)(chang)(chang)(chang)35.64%，其中(zhong)，健(jian)康(kang)消費品業(ye)(ye)務(wu)(wu)(wu)實現(xian)(xian)營(ying)(ying)(ying)收(shou)(shou)2.9億(yi)元(yuan)(yuan)，同(tong)(tong)(tong)比(bi)增長(chang)(chang)(chang)(chang)20.45%；非(fei)處方(fang)藥業(ye)(ye)務(wu)(wu)(wu)實現(xian)(xian)營(ying)(ying)(ying)收(shou)(shou)14.87億(yi)元(yuan)(yuan)，同(tong)(tong)(tong)比(bi)增長(chang)(chang)(chang)(chang)39.06%。處方(fang)藥業(ye)(ye)務(wu)(wu)(wu)實現(xian)(xian)營(ying)(ying)(ying)收(shou)(shou)11.81億(yi)元(yuan)(yuan)，同(tong)(tong)(tong)比(bi)增長(chang)(chang)(chang)(chang)12.23%。中(zhong)藥飲(yin)片(pian)業(ye)(ye)務(wu)(wu)(wu)實現(xian)(xian)營(ying)(ying)(ying)收(shou)(shou)3.46億(yi)元(yuan)(yuan)，同(tong)(tong)(tong)比(bi)增長(chang)(chang)(chang)(chang)37.44%。其他業(ye)(ye)務(wu)(wu)(wu)實現(xian)(xian)營(ying)(ying)(ying)收(shou)(shou)4.61億(yi)元(yuan)(yuan)，同(tong)(tong)(tong)比(bi)下降1.32%。

從具(ju)體產(chan)品(pin)(pin)(pin)來看，核心產(chan)品(pin)(pin)(pin)“康(kang)恩(en)貝(bei)”牌(pai)腸炎寧系列(lie)產(chan)品(pin)(pin)(pin)、“金康(kang)速力(li)”牌(pai)乙酰半(ban)胱氨酸泡(pao)騰片等(deng)呼吸(xi)道類產(chan)品(pin)(pin)(pin)、“康(kang)恩(en)貝(bei)”牌(pai)維C系列(lie)等(deng)健康(kang)消費品(pin)(pin)(pin)以(yi)及“至(zhi)心砃(dan)”牌(pai)麝香(xiang)通心滴(di)丸等(deng)產(chan)品(pin)(pin)(pin)銷(xiao)售(shou)增長(chang)較快。

值(zhi)(zhi)得注意的是，康恩(en)貝上半年歸母凈利(li)潤(run)增長幅(fu)度較高除(chu)了(le)受核心產品銷(xiao)售增長較快的影響(xiang)(xiang)，參股(gu)公(gong)司(si)公(gong)允(yun)價(jia)值(zhi)(zhi)變動和轉讓股(gu)權所帶來投資收益(yi)等非經常性損益(yi)對凈利(li)潤(run)的影響(xiang)(xiang)也(ye)頗為(wei)顯著：其中一部(bu)分來自(zi)公(gong)司(si)參股(gu)的港股(gu)上市(shi)公(gong)司(si)嘉和生物股(gu)份(fen)市(shi)值(zhi)(zhi)變動影響(xiang)(xiang)，本期與上年同期相(xiang)比增加利(li)潤(run)8788.43萬元(yuan)；另一部(bu)分則來自(zi)轉讓江(jiang)西(xi)珍(zhen)視明藥業有(you)限公(gong)司(si)7.84%股(gu)權影響(xiang)(xiang)，確認了(le)股(gu)權處置(zhi)凈利(li)潤(run)8671.61萬元(yuan)。

康恩貝扣非歸母(mu)凈(jing)利潤(run)為(wei)4.15億(yi)元，較上年同期增長33.01%。

封(feng)面(mian)圖片(pian)來源：每(mei)日經(jing)濟新(xin)聞 劉國梅 攝